2024MAY10: Our hosting provider is experiencing intermittent networking issues. We apologize for any inconvenience.

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ.

Nature communications | 2022

Pancreatic intraepithelial neoplasia (PanIN) is a precursor of pancreatic ductal adenocarcinoma (PDAC), which commonly occurs in the general populations with aging. Although most PanIN lesions (PanINs) harbor oncogenic KRAS mutations that initiate pancreatic tumorigenesis; PanINs rarely progress to PDAC. Critical factors that promote this progression, especially targetable ones, remain poorly defined. We show that peroxisome proliferator-activated receptor-delta (PPARδ), a lipid nuclear receptor, is upregulated in PanINs in humans and mice. Furthermore, PPARδ ligand activation by a high-fat diet or GW501516 (a highly selective, synthetic PPARδ ligand) in mutant KRASG12D (KRASmu) pancreatic epithelial cells strongly accelerates PanIN progression to PDAC. This PPARδ activation induces KRASmu pancreatic epithelial cells to secrete CCL2, which recruits immunosuppressive macrophages and myeloid-derived suppressor cells into pancreas via the CCL2/CCR2 axis to orchestrate an immunosuppressive tumor microenvironment and subsequently drive PanIN progression to PDAC. Our data identify PPARδ signaling as a potential molecular target to prevent PDAC development in subjects harboring PanINs.

Pubmed ID: 35562376 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: P30 CA016672
  • Agency: NCI NIH HHS, United States
    Id: R01 CA206539
  • Agency: NCI NIH HHS, United States
    Id: R01 CA195686
  • Agency: NCI NIH HHS, United States
    Id: R01 CA266223
  • Agency: NCI NIH HHS, United States
    Id: R03 CA235106
  • Agency: NCI NIH HHS, United States
    Id: R01 CA142969
  • Agency: NCI NIH HHS, United States
    Id: R01 CA236905
  • Agency: NCI NIH HHS, United States
    Id: K08 CA234222

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


C57BL/6JGpt-Six2em1Cin(LSL-tdTomato)/Gpt (tool)

RRID:IMSR_GPT:T053304

Mus musculus with name C57BL/6JGpt-Six2em1Cin(LSL-tdTomato)/Gpt from IMSR.

View all literature mentions

B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J (tool)

RRID:IMSR_JAX:007914

Mus musculus with name B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J from IMSR.

View all literature mentions

PANC-1 (tool)

RRID:CVCL_0480

Cell line PANC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions